A real-world, retrospective, observational study of dabigatran and rivaroxaban in Turkey: Elderly patients receive inappropriately low dose of rivaroxaban

Basit Öğe Kaydı
dc.contributor.authorYiğiner, Ömer
dc.contributor.authorTezcan, Mehmet
dc.contributor.authorErdal, Emrah
dc.contributor.authorDeğirmencioğlu, Gökhan
dc.contributor.authorAcar, Gürkan
dc.contributor.authorErgelen, Mehmet
dc.contributor.authorÇay, Serkan
dc.contributor.authorÇetin, Hande
dc.contributor.authorÖzçelik, Fatih
dc.contributor.authorDoğan, Mehmet
dc.contributor.authorTokatlı, Alptuğ
dc.contributor.authorÖzmen, Namık
dc.contributor.authorUz, Ömer
dc.contributor.authorKılıçaslan, Fethi
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:56:35Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:56:35Z
dc.date.issued2017
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.descriptionWOS: 000406058200090
dc.description.abstractThromboembolic complications are the most important outcomes of atrial fibrillation (AF). New oral anticoagulants (NOACs) have been presented to protect non-valvular AF patients from thromboembolic complications. In this study, we aimed to evaluate effectiveness and safety of NOACs and also reveal prescribing habits of physicians, retrospectively. NOACs and their effectiveness and safety retrospectively. Patients with non-valvular AF using either rivaroxaban or dabigatran were included in the study in five different tertiary centers. Patients were identified by scanning their medication reports. Appropriate patients were called and face-to-face interviews were done. Follow-ups were carried out on the phone. 183 out of 201 identified patients, taking rivaroxaban and dabigatran, were reached. General clinical characteristics were not significantly different between drug groups. Vascular disease and persistent AF were significantly higher in the rivaroxaban group. The rate of low dose medication in the dabigatran group was higher compared to the rivaroxaban group. Average age of the patients taking low dose medication were prominently higher in both groups. Between high and low dose users of the dabigatran group, creatinine clearance (CrCl) were not differed. Among rivaroxaban group, CrCl of the low dose users were lower than of the high dose users. However, among low-dose-prescribed patients, only 6 out of 38 patients had a CrCl value in the range of 30-49 ml/min, revealing that remaining 32 patients were receiving inappropriately low rivaroxaban dose. The rate of all-cause mortality, thromboembolism and bleeding complications were not statistically significant between the medication groups. While prescribing NOAC for non-valvular AF patients, physicians seem to consider patients' ages rather than CrCl values. In terms of protecting from thromboembolism, rivaroxaban and dabigatran seem to be equally effective and safe.
dc.identifier.citationYiğiner, Ö., Tezcan, M., Erdal, E., Değirmencioğlu, G., Acar, G., Ergelen, M. … Kılıçaslan, F. (2017). A real-world, retrospective, observational study of dabigatran and rivaroxaban in Turkey: Elderly patients receive inappropriately low dose of rivaroxaban. International Journal of Clinical and Experimental Medicine, 10(7), 10634-10642.
dc.identifier.endpage10642
dc.identifier.issn1940-5901
dc.identifier.issue7
dc.identifier.scopusqualityQ3
dc.identifier.startpage10634
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2753
dc.identifier.volume10
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherE-Century Publishing Corp
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAtrial Fibrillation
dc.subjectDabigatran
dc.subjectRivaroxaban
dc.titleA real-world, retrospective, observational study of dabigatran and rivaroxaban in Turkey: Elderly patients receive inappropriately low dose of rivaroxaban
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kilicaslan-Fethi-2017.pdf
Boyut:
336.13 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu